• Thomas Fritsche MD, PhD

  • Physician - Pathology (MD)


    • Pathology
    • 1000 North Oak Avenue LAB Marshfield, WI 54449

Education


1987:
Postdoctoral Associate, James Ford Bell Museum of Natural History, University of Minnesota, Minneapolis, MN
1984:
PhD, Zoology (Parasitology), University of Minnesota, Minneapolis, MN
1984:
Residency, Chief Resident-Department of Laboratory Medicine, University of Washington Medical Center, Seattle, WA
1984:
Fellowship, Clinical Microbiology, Department of Laboratory Medicine, University of Washington Medical Center, Seattle, WA
1982:
Internship, Department of Pathology and Department of Laboratory Medicine, University of Washington Medical Center, Seattle, WA
1981:
MD, University of Minnesota-Medical School, Minneapolis, MN
1975:
Tropical Parasitology, Universidad de Costa Rica (sponsored by the Organization of Tropical Studies)
1975:
MS, Zoology, University of Minnesota, Minneapolis, MN
1973:
BS, Zoology, University of Minnesota, Minneapolis, MN

Work Experience


2013 to Present:
Laboratory Director, Marshfield Labs, a Division of Marshfield Clinic Inc., Marshfield, WI
2009 to Present:
Adjunct Professor of Microbiology, University of Wisconsin-La Crosse, La Crosse, WI
2008 to Present:
Pathologist, Department Head-Section of Clinical Microbiology, Marshfield Labs, a Division of Marshfield Clinic Inc., Marshfield, WI
2008 to Present:
Attending Physician, Marshfield Clinic Inc. - Marshfield Center, Marshfield, WI
2008 to Present:
Attending Physician, MCHS Hospitals Inc. d/b/a Marshfield Medical Center, Marshfield, WI
2005 to 2008:
Director of Clinical Laboratories, JMI Laboratories, North Liberty, IA
2003 to 2005:
Associate Director, JMI Laboratories, North Liberty, IA
1999 to 2003:
Director-American College of Microbiology Accredited Postdoctoral Training Program in Clinical and Public Health Microbiology, University of Washington, Seattle, WA
1996 to 2003:
Head-Clinical Microbiology Division, University of Washington Medical Center, Seattle, WA
1994 to 2003:
Adjunct Associate Professor-Ophthalmology, University of Washington School of Medicine, Seattle, WA
1993 to 2003:
Director-Clinical Microbiology Laboratories, University of Washington Medical Center, Seattle, WA
1992 to 2003:
Associate Professor-Laboratory Medicine and Microbiology, University of Washington School of Medicine, Seattle, WA
1996 to 1999:
Co-Director-American College of Microbiology Accredited Postdoctoral Training Program in Clinical and Public Health Microbiology, University of Washington, Seattle, WA
1990 to 1994:
Research Affiliate-Regional Primate Research Center, University of Washington, Seattle, WA
1984 to 1993:
Associate Director-Clinical Microbiology Laboratories, University of Washington Medical Center, Seattle, WA
1986 to 1992:
Assistant Professor-Laboratory Medicine and Microbiology, University of Washington Medical Center, Seattle, WA
1984 to 1986:
Instructor-Laboratory Medicine and Microbiology, University of Washington School of Medicine, Seattle, WA
1974 to 1977:
Graduate Teaching and Research Assistant-Department of Zoology & Ecology and Department of Behavioral Biology, University of Minnesota, Minneapolis, MN

Board Certifications


1985 to Present:
American Board of Pathology - Clinical Pathology
1999 to Present:
American Board of Medical Microbiology, Recertified

Professional Societies


American Academy of Microbiology , Fellow
American Society of Clinical Pathologists, Fellow
Royal Society of Tropical Medicine & Hygiene , Fellow

Committees


2007 to Present:
Editorial Board, Journal of Chemotherapy, Member

Select Publications


  • Namekata T, Miki K, Kimmey M, Fritsche TR, Hughes D, Moore D, Suzuki K. (2000 April). Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle. Am J Epidemiol. 151(8):820-30.
  • Limaye AP, Turgeon DK, Cookson BT, Fritsche TR. (2000 April). Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J Clin Microbiol. 38(4):1696-7.
  • Limaye AP, Connolly PA, Sagar M, Fritsche TR, Cookson BT, Wheat LJ, Stamm WE. (2000 October). Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med. 343(16):1163-6.
  • Horn M, Wagner M, Müller KD, Schmid EN, Fritsche TR, Schleifer KH, Michel R. (2000 May). Neochlamydia hartmannellae gen. nov., sp. nov. (Parachlamydiaceae), an endoparasite of the amoeba Hartmannella vermiformis. Microbiology. 146(Pt 5):1231-9.
  • Fritsche TR, Horn M, Wagner M, Herwig RP, Schleifer KH, Gautom RK. (2000 June). Phylogenetic diversity among geographically dispersed Chlamydiales endosymbionts recovered from clinical and environmental isolates of Acanthamoeba spp. Appl Environ Microbiol. 66(6):2613-9.
  • Turgeon DK, Fritsche TR. (2001 September). Laboratory approaches to infectious diarrhea. Gastroenterol Clin North Am. 30(3):693-707.
  • Rathinam S, Fritsche TR, Srinivas M, Vijayalakshmi P, Read RW, Gautom RK,...Rao NA. (2001 July). An outbreak of trematode-induced granulomas of the conjunctiva. OPHTHALMOLOGY. 108(7):1223-9.
  • Schielke JE, Selvarangan R, Kyes KB, Fritsche TR. (2002 July). Laboratory diagnosis of Trypanosoma cruzi infection in a colony-raised pigtailed macaque. Contemp Top Lab Anim Sci. 41(4):42-5.
  • Horn M, Fritsche TR, Linner T, Gautom RK, Harzenetter MD, Wagner M. (2002 March). Obligate bacterial endosymbionts of Acanthamoeba spp. related to the beta-Proteobacteria: proposal of 'Candidatus Procabacter acanthamoebae' gen. nov., sp. nov. Int J Syst Evol Microbiol. 52(Pt 2):599-605.
  • Turgeon DK, Novicki TJ, Quick J, Carlson L, Miller P, Ulness BK,...Fritsche TR. (2003 February). Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J Clin Microbiol. 41(2):667-670.
    PubMed ID: 12574264
  • Sader HS, Fritsche TR, Mutnick AH, Jones RN. (2003 November). Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagn Microbiol Infect Dis. 47(3):515-25.
    PubMed ID: 14596971
  • Fritsche TR, Sader HS, Jones RN. (2003 October). Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagn Microbiol Infect Dis. 47(2):435-40.
    PubMed ID: 14522519
  • Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RN. (2003 September). Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 47(1):373-6.
    PubMed ID: 12967753
  • Rhomberg PR, Fritsche TR. (2003). Antibiotic resistance in hospitalized patients: MYSTIC Program (1999-2002). Antibiotics for Clinicians. 7(Suppl 2):2-7.
  • Lee SD, Turgeon DK, Ko CG, Fritsche TR, Surawicz CM. (2003 July). Clinical correlation of toxin and common antigen enzyme immunoassay testing in patients with Clostridium difficile disease. Am J Gastroenterol. 98(7):1569-72.
  • Lai KK, Chan JL, Schmer G, Fritsche TR. (2003 April). Sir Patrick Manson: good medicine for the people of Hong Kong. Hong Kong Med J. 9(2):145-7.
  • Krieger JN, Ross SO, Deutsch LA, Fritsche TR, Riley DE. (2003 July). Counting leukocytes in expressed prostatic secretions from patients with chronic prostatitis/chronic pelvic pain syndrome. UROLOGY. 62(1):30-4.
  • Garcia LS, Smith JW, Fritsche TR. (2003). CUMITECH 30A, Selection and use of laboratory procedures for the diagnosis of parasitic infections of the gastrointestinal tract. American Society of Microbiology, Washington, D.C..
  • Pottumarthy S, Moland ES, Juretschko S, Swanzy SR, Thomson KS, Fritsche TR. (2003 August). NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg Infect Dis. 9(8):999-1002.
    PubMed ID: 12967501
  • Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. (2004 December). Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother. 54(6):1051-6.
    PubMed ID: 15564286
  • Sader HS, Streit JM, Fritsche TR, Jones RN. (2004 November). Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn Microbiol Infect Dis. 50(3):201-4.
    PubMed ID: 15541606
  • Deshpande LM, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. (2004 September). Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn Microbiol Infect Dis. 50(1):73-5.
    PubMed ID: 15380281
  • Sader HS, Streit JM, Fritsche TR, Jones RN. (2004 August). Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates. Diagn Microbiol Infect Dis. 49(4):283-7.
    PubMed ID: 15313534
  • Rhomberg PR, Jones RN, Sader HS, Fritsche TR, MYSTIC Programme Study Group. (2004 August). Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagn Microbiol Infect Dis. 49(4):273-81.
    PubMed ID: 15313533
  • Streit JM, Jones RN, Sader HS, Fritsche TR. (2004 August). Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents. 24(2):111-8.
    PubMed ID: 15288308
  • Jones RN, Deshpande L, Fritsche TR, Sader HS. (2004 July). Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). Diagn Microbiol Infect Dis. 49(3):211-6.
    PubMed ID: 15246512
  • Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. (2004 July). Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 54(1):144-54.
    PubMed ID: 15190031
  • Jones RN, Sader HS, Fritsche TR. (2004 June). Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). Diagn Microbiol Infect Dis. 49(2):147-9.
    PubMed ID: 15183865
  • Jones RN, Fritsche TR, Sader HS. (2004 May). Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagn Microbiol Infect Dis. 49(1):63-5.
    PubMed ID: 15135503
  • Jones RN, Moet GJ, Sader HS, Fritsche TR. (2004 May). Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J Antimicrob Chemother. 53(5):804-7.
    PubMed ID: 15056649
  • Streit JM, Fritsche TR, Sader HS, Jones RN. (2004 February). Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 48(2):137-43.
    PubMed ID: 14972384
  • Fritsche TR, Moet GJ, Jones RN. (2004 September). Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase. Clin Microbiol Infect. 10(9):857-60.
    PubMed ID: 15355422
  • Fritsche TR, Jones RN. (2004 December). Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents. 24(6):567-71.
    PubMed ID: 15555879
  • Epstein JB, Truelove EL, Hanson-Huggins K, Mancl LA, Chen A, Press OW,...Epstein JD. (2004 July). Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Support Care Cancer. 12(7):517-25.
    PubMed ID: 15108100
  • Deshpande LM, Fritsche TR, Jones RN. (2004 August). Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 49(4):231-6.
    PubMed ID: 15313526
  • Anderegg TR, Fritsche TR, Jones RN, Quality Control Working Group. (2004 March). Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide. J Clin Microbiol. 42(3):1386-7.
  • Fritsche TR, Kirby JT, Jones RN. (2004 July). In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis. 49(3):201-9.
    PubMed ID: 15246511
  • Jones RN, Streit JM, Fritsche TR. (2004 February). Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents. 23(2):197-9.
    PubMed ID: 15013046
  • Hooton TM, Besser RE, Foxman B, Fritsche TR, Nicolle LE. (2004 July). Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis. 39(1):75-80.
    PubMed ID: 15206056
  • Herwaldt BL, de Bruyn G, Pieniazek NJ, Homer M, Lofy KH, Slemenda SB,...Limaye AP. (2004 April). Babesia divergens-like infection, Washington State. Emerg Infect Dis. 10(4):622-9.
    PubMed ID: 15200851
  • Jones RN, Fritsche TR, Sader HS, Goldstein BP. (2005 December). Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother. 17(6):593-600.
    PubMed ID: 16433188
  • Sader HS, Fritsche TR, Streit JM, Jones RN. (2005 October). Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003. J Chemother. 17(5):477-83.
    PubMed ID: 16323435
  • Rhomberg PR, Fritsche TR, Streit JM, Jones RN. (2005 October). Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J Chemother. 17(5):459-69.
    PubMed ID: 16323433
  • Jones RN, Sader HS, Fritsche TR. (2005 May). Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis.. 52(1):71-4.
    PubMed ID: 15878447
  • Sader HS, Fritsche TR, Jones RN. (2005 December). Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn Microbiol Infect Dis. 53(4):329-32.
    PubMed ID: 16263233
  • Pottumarthy S, Sader HS, Fritsche TR, Jones RN. (2005 November). Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis? Diagn Microbiol Infect Dis. 53(3):225-31.
    PubMed ID: 16257168
  • Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. (2005 December). Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother. 56(6):1047-52.
    PubMed ID: 16239290
  • Sader HS, Fritsche TR, Jones RN. (2005 July). Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn Microbiol Infect Dis. 52(3):265-73.
    PubMed ID: 16105569
  • Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. (2005 July). Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis. 52(3):209-13.
    PubMed ID: 16105566
  • Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. (2005 July). Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis. 52(3):203-8.
    PubMed ID: 16105565
  • Fritsche TR, Sader HS, Stillwell MG, Dowzicky MJ, Jones RN. (2005 July). Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis. 52(3):195-201.
    PubMed ID: 16105564
  • Fritsche TR, Sader HS, Stillwell MG, Dowzicky MJ, Jones RN. (2005 July). Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis. 52(3):187-93.
    PubMed ID: 16105563
  • Sader HS, Jones RN, Stillwell MG, Dowzicky MJ, Fritsche TR. (2005 July). Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 52(3):181-6.
    PubMed ID: 16105562
  • Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. (2005 August). Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 49(8):3501-12.
    PubMed ID: 16048970
  • Fritsche TR, Sader HS, Toleman MA, Walsh TR, Jones RN. (2005 August). Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. Clin Infect Dis. 41 Suppl 4: :S276-8.
    PubMed ID: 16032565
  • Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN. (2005 July). Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents. 26(1):13-21.
    PubMed ID: 15967640
  • Jones RN, Fritsche TR, Sader HS. (2005 June). Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 52(2):129-33.
    PubMed ID: 15964501
  • Streit JM, Sader HS, Fritsche TR, Jones RN. (2005 December). Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis. 53(4):307-10.
    PubMed ID: 15922534
  • Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN. (2005 May). Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn Microbiol Infect Dis. 52(1):53-8.
    PubMed ID: 15878443
  • Fritsche TR, Sader HS, Cleeland R, Jones RN. (2005 April). Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob Agents Chemother. 49(4):1468-76.
    PubMed ID: 15793128
  • Pottumarthy S, Fritsche TR, Sader HS, Stillwell MG, Jones RN. (2005 April). Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. Int J Antimicrob Agents. 25(4):282-9.
    PubMed ID: 15784306
  • Ross JE, Sader HS, Fritsche TR, Jones RN. (2005 March). Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels. Diagn Microbiol Infect Dis. 51(3):219-21.
    PubMed ID: 15766610
  • Jones RN, Sader HS, Fritsche TR. (2005 February). Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). Diagn Microbiol Infect Dis. 51(2):139-41.
    PubMed ID: 15698721
  • Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR. (2005 February). Emerging epidemic of metallo-beta-lactamase-mediated resistances. Diagn Microbiol Infect Dis. 51(2):77-84.
    PubMed ID: 15698711
  • Pottumarthy S, Fritsche TR, Jones RN. (2005 February). Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn Microbiol Infect Dis. 51(2):147-50.
    PubMed ID: 15698723
  • Pottumarthy S, Fritsche TR, Jones RN. (2005 January). Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: validation report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 51(1):57-62.
    PubMed ID: 15629230
  • McDermott PF, Bodeis-Jones SM, Fritsche TR, Jones RN, Walker RD. (2005 December). Broth microdilution susceptibility testing of Campylobacter jejuni and the determination of quality control ranges for fourteen antimicrobial agents. J Clin Microbiol. 43(12):6136-8.
    PubMed ID: 16333113
  • Fritsche TR, Stillwell MG, Jones RN. (2005 December). Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect. 11(12):974-84.
    PubMed ID: 16307551
  • Fritsche TR, Jones RN. (2005 November). Importance of understanding pharmacokinetic/pharmacodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureus. J Drugs Dermatol. 6(6 Suppl):s4-8.
    PubMed ID: 16300223
  • Collingro A, Toenshoff ER, Taylor MW, Fritsche TR, Wagner M, Horn M. (2005 September). 'Candidatus Protochlamydia amoebophila', an endosymbiont of Acanthamoeba spp. Int J Syst Evol Microbiol. 55(Pt 5):1863-6.
    PubMed ID: 16166679
  • Fedler KA, Jones RN, Sader HS, Fritsche TR. (2006 June). Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003). Diagn Microbiol Infect Dis. 55(2):157-64.
    PubMed ID: 16529904
  • Sader HS, Fritsche TR, Jones RN. (2006 March). Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents. J Clin Microbiol. 44(3):1101-4.
    PubMed ID: 16517904
  • Rhomberg PR, Fritsche TR, Sader HS, Jones RN. (2006 April). Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). Diagn Microbiol Infect Dis. 54(4):249-57.
    PubMed ID: 16466890
  • Jones RN, Stillwell MG, Sader HS, Fritsche TR, Goldstein BP. (2006 February). Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis. 54(2):149-53.
    PubMed ID: 16426793
  • Jones RN, Ross JE, Fritsche TR, Sader HS. (2006 February). Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother. 57(2):279-87.
    PubMed ID: 16326811
  • Jones RN, Sader HS, Fritsche TR, Rhomberg PR. (2006 January). Carbapenem susceptibility discords among Acinetobacter isolates. Clin Infect Dis. 42(1):158.
    PubMed ID: 16323113
  • Rhomberg PR, Fritsche TR, Sader HS, Jones RN. (2006 September). Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn Microbiol Infect Dis. 56(1):57-62.
    PubMed ID: 16631338
  • Pfaller MA, Sader HS, Fritsche TR, Jones RN. (2006 September). Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 56(1):63-8.
    PubMed ID: 16650951
  • Johnson DM, Fritsche TR, Sader HS, Jones RN. (2006 June). Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 27(6):557-60.
    PubMed ID: 16698238
  • Sader HS, Fritsche TR, Jones RN. (2006 July). Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother. 50(7):2330-6.
    PubMed ID: 16801409
  • Jones RN, Fritsche TR, Sader HS, Ross JE. (2006 July). Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. 50(7):2583-6.
    PubMed ID: 16801451
  • Jones RN, Sader HS, Fritsche TR, Hogan PA, Sheehan DJ. (2006 July). Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J Clin Microbiol. 44(7):2622-5.
    PubMed ID: 16825398
  • Sader HS, Streit JM, Fritsche TR, Jones RN. (2006 September). Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect. 12(9):844-52.
    PubMed ID: 16882289
  • Deshpande LM, Sader HS, Fritsche TR, Jones RN. (2006 October). Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004). J Clin Microbiol. 44(10):3775-7.
    PubMed ID: 17021108
  • Deshpande LM, Jones RN, Fritsche TR, Sader HS. (2006 December). Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int J Antimicrob Agents. 28(6):578-81.
    PubMed ID: 17112706
  • Deshpande LM, Jones RN, Fritsche TR, Sader HS. (2006). Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist. 12(4):223-30.
    PubMed ID: 17227206
  • Watters AA, Jones RN, Leeds JA, Denys GA, Sader HS, Fritsche TR. (2006 May). Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J Antimicrob Chemother. 57(5):914-23.
    PubMed ID: 16549511
  • Pottumarthy S, Fritsche TR, Jones RN. (2006 February). Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes. Diagn Microbiol Infect Dis. 54(2):127-34.
    PubMed ID: 16423492
  • Messer SA, Jones RN, Fritsche TR. (2006 May). International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol. 44(5):1782-7.
    PubMed ID: 16672407
  • Kirby JT, Fritsche TR, Jones RN. (2006 September). Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagn Microbiol Infect Dis. 56(1):75-82.
    PubMed ID: 16876375
  • Jones RN, Ross JE, Fritsche TR, Sader HS. (2006). Comment on: Linezolid resistance in coagulase-negative staphylococci. J Antimicrob Chemother. 58(4):279-87.
  • Johnson DM, Stillwell MG, Fritsche TR, Jones RN. (2006 September). Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis.. 56(1):69-74.
    PubMed ID: 16546341
  • Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ. (2006 February). Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn Microbiol Infect Dis. 54(2):83-7.
    PubMed ID: 16458124
  • Fritsche TR, Rennie RP, Goldstein BP, Jones RN. (2006 August). Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms. J Clin Microbiol. 44(8):2988-90.
    PubMed ID: 16891523
  • Streit JM, Jones RN, Toleman MA, Stratchounski LS, Fritsche TR. (2006 May). Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003). Int J Antimicrob Agents.. 27(5):367-75.
    PubMed ID: 16647842
  • Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. (2007 August). Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents. 30(2):143-9.
    PubMed ID: 17531446
  • Jones RN, Fritsche TR, Sader HS, Ross JE. (2007 November). LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis. 59(3):309-17.
    PubMed ID: 17720350
  • Jones RN, Fritsche TR, Sader HS, Ross JE. (2007 October). Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis. 59(2):199-209.
    PubMed ID: 17908617
  • Sader HS, Mallick R, Kuznik A, Fritsche TR, Jones RN. (2007 December). Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. Int J Antimicrob Agents. 30(6):514-20.
    PubMed ID: 17959359
  • Jones RN, Sader HS, Fritsche TR, Janechek MJ. (2007 December). Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis. 59(4):467-72.
    PubMed ID: 17997070
  • Jones RN, Sader HS, Fritsche TR, Pottumarthy S. (2007 January). Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 57(1):109-16.
    PubMed ID: 16930923
  • Sader HS, Hsiung A, Fritsche TR, Jones RN. (2007 March). Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis. 57(3):341-4.
    PubMed ID: 17141461
  • Biedenbach DJ, Ross JE, Fritsche TR, Sader HS, Jones RN. (2007 March). Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J Clin Microbiol. 45(3):998-1004.
    PubMed ID: 17215346
  • Ross JE, Fritsche TR, Sader HS, Jones RN. (2007 March). Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents. 29(3):295-301.
    PubMed ID: 17239570
  • Fritsche TR, Sader HS, Jones RN. (2007 May). Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn Microbiol Infect Dis. 58(1):19-26.
    PubMed ID: 17383139
  • Sader HS, Fritsche TR, Jones RN. (2007 May). In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). Diagn Microbiol Infect Dis. 58(1):27-32.
    PubMed ID: 17383140
  • Jones RN, Fritsche TR, Sader HS, Stillwell MG. (2007 May). Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn Microbiol Infect Dis. 58(1):9-17.
    PubMed ID: 17408903
  • Jones RN, Sader HS, Stillwell MG, Fritsche TR. (2007 May). Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 58(1):1-7.
    PubMed ID: 17408904
  • Sader HS, Watters AA, Fritsche TR, Jones RN. (2007 April). Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 7 :29.
    PubMed ID: 17442104
  • Jones RN, Sader HS, Fritsche TR. (2007 May). Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis. 52(1):71-4.
    PubMed ID: 15878447
  • Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL,...Drusano GL. (2007 June). Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis.. 195(12):1818-27.
    PubMed ID: 17492598
  • Sader HS, Jacobs MR, Fritsche TR. (2007 March). Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis. 57(3 Suppl):5S-12S.
    PubMed ID: 17292577
  • Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB, Goldstein BP. (2007 October). Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol. 45(10):3151-4.
    PubMed ID: 17670919
  • Moet GJ, Jones RN, Biedenbach DJ, Stillwell MG, Fritsche TR. (2007 January). Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 57(1):7-13.
    PubMed ID: 17059876
  • Hadley JA, Fritsche TR. (2007 March). The role of newer orally administered cephalosporins in contemporary outpatient practice. Diagn Microbiol Infect Dis. 57(3 Suppl):1S-3S.
    PubMed ID: 17292574
  • Fritsche TR, McDermott PF, Shryock TR, Walker RD, Morishita TY. (2007 August). Agar dilution and disk diffusion susceptibility testing of Campylobacter spp. J Clin Microbiol. 45(8):2758-9; author reply 2759..
    PubMed ID: 17675457
  • Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. (2007 June). Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 58(2):163-70.
    PubMed ID: 17368801
  • Sader HS, Watters AA, Fritsche TR, Jones RN. (2008 February). Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers. J Chemother. 20(1):28-32.
    PubMed ID: 18343740
  • Fritsche TR, Rhomberg PR, Sader HS, Jones RN. (2008 May). Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. J Antimicrob Chemother. 61(5):1092-8.
    PubMed ID: 18310135
  • Sader HS, Fritsche TR, Jones RN. (2008 March). Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 52(3):1153-5.
    PubMed ID: 18180353
  • Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. (2008 February). Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 52(2):570-3.
    PubMed ID: 18070960
  • Fritsche TR, Rhomberg PR, Sader HS, Jones RN. (2008 April). In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 60(4):399-403.
    PubMed ID: 18178361
  • Fritsche TR, Rhomberg PR, Sader HS, Jones RN. (2008 March). Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. Antimicrob Agents Chemother. 52(3):1187-9.
    PubMed ID: 18180345
  • Sader HS, Fritsche TR, Jones RN. (2008 October). Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients. J Chemother. 20(5):570-6.
    PubMed ID: 19028618
  • Jones RN, Fritsche TR, Sader HS. (2008 October). Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates. Int J Infect Dis. 52(10):3763-75.
    PubMed ID: 18573936
  • Mendes RE, Fritsche TR, Sader HS, Jones RN. (2008 April). Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates. Clin Infect Dis. 46(8):1324-6.
    PubMed ID: 18444879
  • Castanheira M, Fritsche TR, Sader HS, Jones RN. (2008 April). RmtD 16S RNA methylase in epidemiologically unrelated spm-1-producing Pseudomonas aeruginosa isolates from Brazil. Antimicrob Agents Chemo. 52(4):1587-8.
    PubMed ID: 18367713
  • Fritsche TR, Biedenbach DJ, Jones RN. (2008 April). Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006). J Chemother. 20(2):170-4.
    PubMed ID: 18467241
  • Mera R, Miller LA, Fritsche TR, Jones RN. (2008 June). Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist.. 14(2):101-7.
    PubMed ID: 18491947
  • Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. (2008 May). Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microbiol Infect Dis. 61(1):96-102.
    PubMed ID: 18384996
  • Jones RN, Fritsche TR, Moet GJ. (2008 May). In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Diagn Microbiol Infect Dis.. 61(1):76-9.
    PubMed ID: 18221852
  • Gales AC, Sader HS, Fritsche TR. (2008 April). Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis. 60(4):421-7.
    PubMed ID: 18068934
  • Fritsche TR, Sader HS, Jones RN. (2008 May). Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis. 61(1):86-95.
    PubMed ID: 18385000
  • Fritsche TR, Castanheira M, Miller GH, Jones RN, Armstrong ES. (2008 May). Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America. Antimicrob Agents Chemother. 52(5):1843-5.
    PubMed ID: 18347105
  • Biedenbach DJ, Jones A, Fritsche TR. (2008 June). Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. Diagn Microbiol Infect Dis. 61(2):240-4.
    PubMed ID: 18353594
  • Fritsche TR, Sader HS, Stillwell MG, Jones RN. (2009 April). Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007). Diagn Microbiol Infect Dis. 63(4):440-6.
    PubMed ID: 19302928
  • Sader HS, Fritsche TR, Jones RN. (2009 May). Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates. Antimicrob Agents Chemother. 53(5):2171-5.
    PubMed ID: 19289528
  • Sader HS, Fritsche TR, Jones RN. (2009 March). Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients. Int J Infect Dis. 13(2):291-5.
    PubMed ID: 18938097
  • Mendes RE, Denys GA, Fritsche TR, Jones RN. (2009 February). Case Report of Aurantimonas altamirensis Bloodstream Infection. J Clin Microbiol. 47(2):514-5.
    PubMed ID: 19036934
  • Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, Taracila M,...Bonomo RA [including Fritsche TR.] (2009 January). Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone. J Biol Chem. 284(2):945-53.
    PubMed ID: 18955486
  • Fritsche TR, Biedenbach DJ, Jones RN. (2009 March). Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea. Antimicrob Agents Chemother. 53(3):1221-4.
    PubMed ID: 19114678
  • Bremner JB, Keller PA, Pyne SG, Boyle TP, Brkic Z, David DM,...Rhodes DI [including Bhavnani S.] (2010). Binaphthyl-based dicationic peptoids with therapeutic potential. Angew Chem Int Ed Engl. 49(3):537-40.
    PubMed ID: 20014083
  • Lindquist T, Maxwell A, Miller T, Win'E T, Novicki TJ, Fritsche TR,...Montoya M. (2011 March). Preparation of corneal donor eyes comparing 1% versus 5% povidone-iodine. Cornea. 30(3):333-7.
    PubMed ID: 21045655
  • Lin Y, Barker E, Kislow JL, Kaldhone PR, Stemper ME, Moore FM,...Shukla SK [including Hall MC, Fritsche TR, Novicki TJ.] (2011 March). Evidence of Multiple Virulence Subtypes in Nosocomial and Community-Associated MRSA Genotypes in Companion Animals from the Upper Midwestern and Northeastern United States. Clinical Medicine & Research. 9(1):7-16.
    PubMed ID: 20739580
  • Weyhmiller JA, Baldauf MC, Olson BJ, Novicki TJ, Fritsche TR. (2013). Performance Characteristics of Mass Spectrometry for the Rapid Identification of Cultured Bacterial pathogens: potential for improving laboratory reporting in patients receiving bacterially-contaminated units. Transfusion. 53(Suppl P):201A.
  • Schotthoefer AM, Meece JK, Ivacic LC, Bertz PD, Zhang KQi, Weiler T,...Fritsche TR [including Uphoff TS.] (2013 July). Comparison of a real-time PCR Method with serology and blood smear analysis for diagnosis of human anaplasmosis:importance of Infection time course for optimal test utilization. JOURNAL OF CLINICAL MICROBIOLOGY. 51(7):2147-53.
    PubMed ID: 23637292
  • Bibbo C, Fritsche TR, Stemper ME, Hall MC. (2013 September). Flap infection associated with medicinal leeches in reconstructive surgery: two new drug-resistant organisms. JOURNAL OF RECONSTRUCTIVE MICROSURGERY. 29(7):457-60.
    PubMed ID: 23599212
  • Schotthoefer AM, Meece JK, Fritsche TR. (2014 June). A clinical, diagnostic, and ecologic perspective on human anaplasmosis in the Upper Midwest. WMJ. 113(3):107-14; quiz 115.
    PubMed ID: 25118439
  • Bortolaia V, Hansen KH, Nielsen CA, Fritsche TR, Guardabassi L. (2014 June). High diversity of plasmids harbouring blaCMY-2 among clinical Escherichia coli isolates from humans and companion animals in the upper Midwestern USA JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 69(6):1492-6.
    PubMed ID: 24500191
  • Epperla N, Kattamanchi S, Fritsche TR. (2015 June). Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis. Clinical Medicine & Research. 13(2):85-8.
    PubMed ID: 25487239